Clinical Trials Directory

Trials / Unknown

UnknownNCT06184893

Rheumatoid Arthritis-associated Interstitial Lung Disease Definition

Multi-centric Prospective and Observational Study of Prevalence and Incidence of Interstitial Lung Diseases in Patients With Rheumatoid Arthritis

Status
Unknown
Phase
Study type
Observational
Enrollment
250 (estimated)
Sponsor
Centre Hospitalier Universitaire de Liege · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers

Summary

This is a prospective multicenter study in southern Belgium to determine the prevalence and incidence of interstitial lung disease in patients with rheumatoid arthritis (RA).

Detailed description

This is a prospective multi-centric longitudinal study of the prevalence and incidence of pulmonary diseases in patients with RA. During one year, patients with a RA diagnosis (according to the criteria of the American Society of Rheumatology) in the south of Belgium will be enrolled on a voluntary basis. If available, data including quality of life and symptoms questionnaires, medical examinations, 6-minute walk-tests, pulmonary function tests and chest CT will be collected during two years. Furthermore, patients could be included (if available data) in two additional sub-cohorts: * "RAIDbio" sub-cohort studying biomarkers: volatile organic compounds, induced sputum and blood biomarkers; * "RAIDomix" sub-cohort studying radiomic patterns (based on high resolution computed tomography of the chest). Due to a non-specific and poor clinical expression at beginning, there is currently an under-diagnosis of rheumatoid arthritis associated-interstitial lung disease (RA-ILD) at an early stage and we assume that an annual pneumological follow-up, search of early biomarkers and a radiomic approach of RA patients will overcome this issue. This should lead to a better follow-up and management (including the use of anti-fibrotic therapies in the future) of these patients and ultimately to a decrease in morbidity and mortality.

Conditions

Timeline

Start date
2023-11-20
Primary completion
2025-10-01
Completion
2025-10-01
First posted
2023-12-28
Last updated
2023-12-28

Locations

1 site across 1 country: Belgium

Source: ClinicalTrials.gov record NCT06184893. Inclusion in this directory is not an endorsement.